COR.NYSECencora, INC
DEF: Cencora Reports Strong Fiscal 2025, Strategic Growth
Sentiment:
Definitive Proxy Statement
Cencora achieved robust fiscal 2025 financial performance with 40% total shareholder return and $321.3 billion in revenue, driven by its pharmaceutical-centric strategy and key acquisitions.
Capital raiseThe Finance Committee provides oversight of the company's capital structure and reviews funding and capital needs, making recommendations to the Board.The Finance Committee reviews and proposes the issuance or sale of stock, stock repurchases, redemptions, and splits.The company returned nearly $900 million to shareholders in fiscal 2025 through dividends and $435 million in share repurchases.
Better than expectedFiscal 2025 revenue increased by 9.3% to $321.3 billion.Adjusted Operating Income grew by 15.8% to $4.2 billion.Adjusted Diluted EPS rose by 16.3% to $16.00.Total Shareholder Return was 40%.Adjusted Free Cash Flow of $3.0 billion exceeded the target of $2.0 billion.Fiscal 2023 performance share awards achieved a 226.4% payout, significantly above target, with relative TSR at the 93rd percentile against the S&P 500 Health Care Providers & Services Industry Index.
Summary
- Cencora reported fiscal 2025 revenue of $321.3 billion, an increase of 9.3% year-over-year.
- Total Shareholder Return (TSR) for fiscal 2025 was 40%.
- Adjusted Operating Income grew by 15.8% to $4.2 billion, and Adjusted Diluted EPS increased by 16.3% to $16.00.
- Adjusted Free Cash Flow for fiscal 2025 was $3.0 billion.
- The company completed the acquisition of Retina Consultants of America, a leading management services organization.
- Cencora announced plans to invest $1.0 billion through 2030 to strengthen its U.S. distribution network and expand capacity.
- Robert P. Mauch successfully transitioned into the role of President and Chief Executive Officer on October 1, 2024, succeeding Steven H. Collis.
- D. Mark Durcan transitioned from Lead Independent Director to Board Chair on October 1, 2025.
- The Board saw new independent directors Lori J. Ryerkerk and Ellen G. Cooper join, while Ornella Barra and Steven H. Collis retired.
- Shareholders will vote on the election of 11 directors, an advisory vote on fiscal 2025 executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026 at the Annual Meeting on March 5, 2026.
Sentiment
Score: 8
Explanation: The filing presents strong financial results, successful strategic execution, and positive governance updates, indicating a very favorable outlook despite a minor underperformance in one segment.
Positives
- Strong financial performance in fiscal 2025, with revenue up 9.3% to $321.3 billion, Adjusted Operating Income up 15.8% to $4.2 billion, and Adjusted Diluted EPS up 16.3% to $16.00.
- Achieved a Total Shareholder Return (TSR) of 40% in fiscal 2025.
- Adjusted Free Cash Flow of $3.0 billion exceeded the target of $2.0 billion for fiscal 2025.
- Successfully executed the CEO succession plan with Robert P. Mauch assuming leadership.
- Strategic acquisition of Retina Consultants of America enhances service offerings and supports community-based practitioners.
- Commitment to invest $1.0 billion through 2030 to strengthen the U.S. distribution network and expand capacity.
- Returned nearly $900 million to shareholders in fiscal 2025 through dividends and $435 million in share repurchases.
- The fiscal 2023 performance share awards (2023-2025 period) resulted in a 226.4% payout, significantly above target, with relative TSR at the 93rd percentile against the S&P 500 Health Care Providers & Services Industry Index.
- Board composition was strengthened with the addition of two new independent directors and a transition to an independent Board Chair, with 10 out of 11 director nominees being independent.
Negatives
- A discretionary reduction was applied to the NEO cash bonus payout, lowering it from a calculated 185.3% to 181.3%, due to the underperformance of a business within the International Healthcare Solutions reportable segment.
Risks
- Risks associated with government regulation.
- Risks related to strategic objectives, business plan, and operations.
- Risks concerning the distribution of controlled substances, including the opioid epidemic.
- Corporate responsibility risks.
- Compensation-related risks.
- Information technology risks, including cybersecurity threats and the responsible integration of advanced technologies like AI.
- Capital structure risks.
- Legal and regulatory compliance risks, including significant litigation and internal/government investigations.
- Enterprise-wide risks.
Future Outlook
Cencora is positioned for continued success in fiscal 2026 and beyond, driven by its pharmaceutical-centric strategy, enhanced service offerings, and strategic investments. The company plans to invest $1.0 billion through 2030 to strengthen its U.S. distribution network and expand capacity, while strategically refocusing its portfolio to align with long-term growth priorities. This approach aims to further strengthen Cencora's position as an end-to-end healthcare company and expand its leadership in higher-margin, high-growth businesses.
Management Comments
- "Fiscal 2025 was a pivotal year for Cencora as we advanced the company's pharmaceutical-centric strategy, guided by its strategic drivers and growth priorities."
- "We believe these actions contributed to Cencora's fiscal 2025 revenue of $321.3 billion and total shareholder return of 40%, and have positioned Cencora for continued success in fiscal 2026 and beyond."
- "We believe that Cencora is well-positioned to increase value for our stakeholders, now and in the future, through the strength of our well-defined strategy and purpose-driven culture."
Industry Context
Cencora operates as a leading global pharmaceutical solutions organization, partnering with innovators and care providers across the value chain. Its strategy to expand in specialty pharmaceuticals and enhance patient access aligns with broader healthcare trends focusing on specialized care and efficient drug delivery. The acquisition of Retina Consultants of America and planned investment in its distribution network reflect a strategic move towards strengthening its end-to-end healthcare capabilities and supporting community-based practitioners, which are key trends in the evolving healthcare delivery landscape.
Comparison to Industry Standards
- Fiscal 2023 performance share awards included a relative TSR modifier, with Cencora achieving 93rd percentile performance against the S&P 500 Health Care Providers & Services Industry Index.
- The S&P 500 Health Care Providers & Services Industry Index, used for TSR comparison, includes companies such as Cardinal Health, Inc., McKesson Corporation, Elevance Health, Inc., HCA Healthcare, Inc., Humana Inc., and UnitedHealth Group Incorporated.
- Executive compensation is benchmarked against a peer group that includes direct competitors like Cardinal Health, Inc. and McKesson Corporation, as well as other companies with comparable financial and operational profiles, with the aim of aligning total direct compensation with the median of this peer group.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President and Chief Executive Officer | Steven H. Collis | Robert P. Mauch | 2024-10-01 | Successful CEO succession plan. |
| Executive Chairman | Steven H. Collis | NA | 2025-09-30 | Retirement and completion of CEO leadership transition. |
| Board Chair | Lead Independent Director (D. Mark Durcan) | D. Mark Durcan | 2025-10-01 | Transition from Lead Independent Director to independent Board Chair following CEO succession. |
| Independent Director | NA | Lori J. Ryerkerk | 2025-06-01 | New appointment to strengthen board oversight. |
| Independent Director | NA | Ellen G. Cooper | 2026-01-20 | New appointment to strengthen board oversight. |
| Director | Ornella Barra | NA | 2025-05-27 | Resigned from the Board. |
| Audit Committee Chair | Dennis M. Nally | Werner Baumann | 2025-03-06 | Committee rotation following the 2025 Annual Meeting of Shareholders. |
| Audit Committee Member | NA | Lauren M. Tyler | 2025-03-06 | New appointment to the committee following the 2025 Annual Meeting of Shareholders. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Leadership Structure | Appointment of an independent Board Chair (D. Mark Durcan) effective October 1, 2025, following the successful CEO succession and retirement of the Executive Chairman. | 2025-10-01 | Enhances independent oversight and aligns with best governance practices. |
| Board Composition | Addition of two new independent directors (Lori J. Ryerkerk and Ellen G. Cooper) and the retirement of two directors (Ornella Barra, Steven H. Collis), resulting in 10 out of 11 directors being independent if all nominees are elected. Eight directors have joined the Board in the past five years. | 2025-06-01 | Strengthens board oversight, brings new perspectives, and reflects a continued focus on thoughtful board composition and refreshment. |
| Director Tenure Policy | Lon R. Greenberg's Board service was extended for an additional year despite reaching 75, due to his deep knowledge of the company and leadership during new director integration. | 2026-03-05 | Provides continuity and leverages deep institutional knowledge during a period of board refreshment. |
| Board Evaluation Process | In fiscal 2025, the Board engaged an independent governance consultant to facilitate an in-depth assessment of its effectiveness, leading to recommendations for enhancing board oversight. | 2025-09-30 | Supports ongoing board refreshment and succession planning efforts, ensuring effective governance and alignment with company priorities. |
| Code of Ethics and Business Conduct | The Code of Ethics and Business Conduct was most recently updated. | 2025-11-01 | Ensures compliance with evolving ethical standards and regulatory requirements. |
| Compensation Recoupment Policy | The Dodd-Frank Compensation Recoupment Policy was adopted in November 2023, and the broader Compensation Recoupment Policy was amended in 2023 to ensure compliance with Dodd-Frank clawback rules. | 2023-11-01 | Enhances accountability for executive officers and aligns compensation practices with regulatory requirements and shareholder interests. |
| Committee Structure | All five standing Board committees are chaired by and composed solely of independent directors, with periodic rotation of committee chairs and assignments. | NA | Ensures independent oversight and enhances the effectiveness of committee responsibilities. |
Legal Proceedings
- A Special Litigation Committee was formed in January 2024 to review a derivative complaint related to the distribution of controlled substances. A settlement of this matter was approved by the Delaware Court of Chancery on November 13, 2025.
- The company is involved in ongoing litigation related to the distribution of opioids, with the Board and Compliance and Risk Committee receiving at least quarterly updates on the status of pending litigation.
- A Special Litigation Committee formed in 2020 to review a derivative complaint related to Medical Initiatives, Inc. was dissolved in the first quarter of fiscal 2025 after the matter was dismissed in September 2024.
Related Party Transactions
- Transactions between Cencora and Walgreens Boots Alliance, Inc. (WBA) accounted for approximately 25% of Cencora's revenues and 38% of its accounts receivable, net, as of September 30, 2025.
- WBA ceased to control more than 5% of Cencora's Common Stock in June 2025, which ended WBA's right to designate a director to Cencora's Board.
- Cencora has a 10-year pharmaceutical distribution agreement (US PVA) and a generics purchasing services arrangement (WBAD Arrangement) with WBA, both extended by three years through 2029.
- A distribution agreement is in place to supply branded and generic pharmaceutical products to WBA's Boots pharmacies in the United Kingdom through 2031.
Stakeholder Impact
- Shareholders: Benefited from strong financial performance, including a 40% TSR and nearly $900 million returned through dividends and share repurchases. Enhanced corporate governance and alignment of executive compensation with performance aim to protect and advance long-term interests.
- Employees: The company's commitment to fostering a culture where industry-leading talent can grow and lead, along with a developed 2030 Talent and Culture Strategy, supports employee development and engagement. Standard employee benefits and deferred compensation plans are in place.
- Customers: Will benefit from enhanced service offerings, expanded access to high-quality care through strategic acquisitions like Retina Consultants of America, and a strengthened U.S. distribution network, ensuring secure and reliable delivery of pharmaceuticals.
- Patients: The pharmaceutical-centric strategy and efforts to expand access to high-quality care and innovative research are aimed at improving the lives of people and animals globally, ensuring safe access to FDA-approved medications.
- Regulatory Authorities: The company's sophisticated diversion control program and adherence to legal and regulatory requirements, including regular reporting to the DEA, demonstrate a commitment to compliance and responsible operations.
Next Steps
- Hold the Annual Meeting of Shareholders on March 5, 2026, to elect directors, conduct an advisory vote on executive compensation, and ratify the appointment of Ernst & Young LLP.
- Continue investment of $1.0 billion through 2030 to strengthen the U.S. distribution network and expand capacity.
- Ongoing strategic refocusing of the company's portfolio to align with long-term growth priorities.
- Annual review of CEO and executive officer succession plans.
- The next say-on-pay advisory vote will be held at the 2027 Annual Meeting of Shareholders.
- The next say-on-frequency advisory vote will be held at the 2029 Annual Meeting of Shareholders.
Key Dates
| Date | Description |
|---|---|
| 2004-05-01 | Board adopted the Code of Ethics and Business Conduct. |
| 2011-07-01 | Steven H. Collis became President and CEO. |
| 2013-05-01 | Lon R. Greenberg joined the Board. |
| 2014-03-01 | Mr. Durcan served as a director of MWI Veterinary Supply, Inc. |
| 2014-03-06 | Ceased using the Equity Incentive Plan for issuances of equity awards. |
| 2015-01-01 | Ornella Barra was designated to the Board by Walgreens Boots Alliance, Inc. (WBA). |
| 2015-02-01 | Acquired MWI Veterinary Supply, Inc. |
| 2016-03-01 | Steven H. Collis became Chairman of the Board. |
| 2016-05-01 | Werner Baumann became Chief Executive Officer and Chairman of the Board of Management of Bayer AG. |
| 2017-05-01 | Mr. Durcan retired from Micron Technology, Inc. |
| 2017-02-01 | Mr. Durcan joined the Board of St. Lukes Health System of Idaho. |
| 2017-10-01 | Mr. Durcan joined the Board of Advanced Micro Devices, Inc. |
| 2018-04-01 | Mr. Durcan joined the Board of Veoneer. |
| 2019-05-01 | Lori J. Ryerkerk became Chief Executive Officer and President of Celanese Corporation. |
| 2020-01-01 | Dennis M. Nally joined the Board. |
| 2020-01-01 | Werner Baumann became Chief Sustainability Officer of Bayer AG. |
| 2020-04-01 | Lori J. Ryerkerk became Chairman of the Board of Celanese Corporation. |
| 2020-04-01 | Mr. Durcan joined the Board of ASML Holding N.V. |
| 2020-06-01 | Mr. Durcan joined the Board of Trustees of Rice University. |
| 2021-06-01 | Acquired a majority of WBA's Alliance Healthcare businesses for $6.275 billion in cash and two million shares of Common Stock. |
| 2022-10-01 | Lorence H. Kim, M.D. joined the Board. |
| 2022-11-09 | The Compensation Committee adopted an executive severance policy. |
| 2022-11-01 | Fiscal 2023 performance share awards were granted. |
| 2023-01-01 | Redonda G. Miller, M.D. joined the Board. |
| 2023-01-01 | Lorence H. Kim, M.D. became a Venture Partner at Ascenta Capital. |
| 2023-03-01 | D. Mark Durcan became Lead Independent Director. |
| 2023-05-01 | Werner Baumann retired from Bayer AG. |
| 2023-05-01 | Ellen G. Cooper assumed the role of Chairman of Lincoln National Corporation. |
| 2023-10-01 | Werner Baumann joined the Board. |
| 2023-10-01 | Lauren M. Tyler joined the Board. |
| 2023-11-01 | The Compensation Committee adopted the Dodd-Frank Compensation Recoupment Policy. |
| 2024-01-01 | The Benefit Restoration Plan was merged into the Deferred Compensation Plan. |
| 2024-01-12 | A Special Litigation Committee was formed to review a derivative complaint related to the distribution of controlled substances. |
| 2024-03-12 | The company and Mr. Collis entered into an employment, transition, and release agreement (Collis Employment Agreement). |
| 2024-08-01 | Date used for determining the total employee population for CEO pay ratio calculation. |
| 2024-09-01 | Medical Initiatives, Inc. derivative complaint matter was dismissed. |
| 2024-09-30 | Steven H. Collis retired as Executive Chairman and director. |
| 2024-10-01 | Robert P. Mauch assumed the role of President and CEO. Steven H. Collis assumed the role of Executive Chairman of the Board. D. Mark Durcan transitioned to Board Chair. |
| 2024-11-20 | NEOs' base salaries were adjusted, and fiscal 2025 annual equity awards were granted. |
| 2025-03-06 | Annual Meeting of Shareholders. Ms. Tyler was appointed to the Audit Committee and Mr. Baumann assumed the role of Chair of the Audit Committee. |
| 2025-05-27 | Ornella Barra retired from the Board. |
| 2025-06-01 | Lori J. Ryerkerk joined the Board as a new independent director. |
| 2025-06-01 | Walgreens Boots Alliance, Inc. (WBA) ceased to control more than 5% of Cencora's Common Stock. |
| 2025-09-30 | Fiscal year 2025 ended. |
| 2025-11-01 | The Code of Ethics and Business Conduct was most recently updated. |
| 2025-11-13 | The Delaware Court of Chancery approved a settlement of the Special Litigation Committee matter related to controlled substances. |
| 2026-01-12 | Record date for shareholders to vote at the 2026 Annual Meeting. |
| 2026-01-20 | Ellen G. Cooper joined the Board as a new independent director. |
| 2026-01-22 | Notice and proxy statement, along with the Annual Report on Form 10-K for fiscal year ended September 30, 2025, were made available to shareholders. |
| 2026-03-02 | Deadline for voting 401(k) or employee stock purchase plan shares for the 2026 Annual Meeting. |
| 2026-03-04 | Deadline for internet or telephone proxy voting for the 2026 Annual Meeting. |
| 2026-03-05 | 2026 Annual Meeting of Shareholders to be held virtually. |
| 2026-09-24 | Deadline for shareholder proposals for inclusion in the 2027 Annual Meeting proxy statement. |
| 2026-11-05 | Earliest date for advance written notice of shareholder nominations for director election at the 2027 Annual Meeting. |
| 2026-12-05 | Latest date for advance written notice of shareholder nominations for director election at the 2027 Annual Meeting. |
| 2027-09-30 | End of the three-year performance period for fiscal 2025 performance share awards. |
| 2027-03-05 | Next say-on-pay advisory vote will be held at the 2027 Annual Meeting of Shareholders. |
| 2029-03-05 | Next say-on-frequency advisory vote will be held at the 2029 Annual Meeting of Shareholders. |
Recommendation
holdCencora demonstrates strong financial performance and strategic execution, including significant revenue and EPS growth, and a high TSR. The company is actively investing in its future and has a robust governance structure. However, the stock has already seen a substantial 40% return in fiscal 2025, suggesting much of the positive news may be priced in. While the outlook is positive, a 'hold' recommendation reflects the strong past performance and the need for further catalysts to drive significant additional upside, balancing the positives with the current valuation.
Keywords
Pharmaceutical solutions, Healthcare distribution, SEC filing, Corporate governance, Executive compensation, Risk management, Cencora, COR, Proxy statement, Shareholder meeting, Board of directors, Financial performance, Specialty pharmaceuticals, M&A, Retina Consultants of America, Supply chain, Cybersecurity, Opioid epidemic, Non-GAAP financial measures
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.